APA način citiranja

Jorge, S. E., Schulman, S., Freed, J. A., VanderLaan, P. A., Rangachari, D., Kobayashi, S. S., . . . Costa, D. B. (2015). Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer.

Čikaški stil citiranja

Jorge, Susan E., Sol Schulman, Jason A. Freed, Paul A. VanderLaan, Deepa Rangachari, Susumu S. Kobayashi, Mark S. Huberman, i Daniel B. Costa. "Responses to the Multitargeted MET/ALK/ROS1 Inhibitor Crizotinib and Co-occurring Mutations in Lung Adenocarcinomas With MET Amplification or MET Exon 14 Skipping Mutation." Lung Cancer 2015.

MLA način citiranja

Jorge, Susan E., et al. "Responses to the Multitargeted MET/ALK/ROS1 Inhibitor Crizotinib and Co-occurring Mutations in Lung Adenocarcinomas With MET Amplification or MET Exon 14 Skipping Mutation." Lung Cancer 2015.